THZ1 (Figure 7, 47) used as a cyclin-dependent kinase 7 (CDK7) inhibitor reduces cell viability and induces apoptosis in human renal cell carcinoma. Here, CDK7 is linked to hereditary clear cell renal cell carcinoma.